Business Segments · D&A
MedSurg and Neurotechnology — D&A
Stryker MedSurg and Neurotechnology — D&A decreased by 3.4% to $56.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.7%, from $60.00M to $56.00M. Over 3 years (FY 2021 to FY 2024), MedSurg and Neurotechnology — D&A shows a downward trend with a -26.2% CAGR.
Analysis
StatementSegment
CategoryProfitability
SignalContext dependent
VolatilityStable
First reportedQ1 2019
Last reportedQ3 2025
Rolls up toD&A
How to read this metric
Rising levels may indicate significant recent capital investment or high levels of acquired intangible assets being written down.
Detailed definition
Represents the systematic allocation of the cost of tangible and intangible assets over their useful lives within the Me...
Peer comparison
Standard accounting metric for capital-intensive industries like medical device manufacturing.
Metric ID:
syk_segment_medsurg_and_neurotechnology_depreciation_and_amortizationHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $129.50M | $129.50M | $129.50M | $135.00M | $135.00M | $135.00M | $135.00M | $141.00M | $141.00M | $141.00M | $141.00M | $54.00M | $56.00M | $60.00M | $38.00M | $57.00M | $58.00M | $56.00M |
| QoQ Change | — | +0.0% | +0.0% | +4.2% | +0.0% | +0.0% | +0.0% | +4.4% | +0.0% | +0.0% | +0.0% | -61.7% | +3.7% | +7.1% | -36.7% | +50.0% | +1.8% | -3.4% |
| YoY Change | — | — | — | — | +4.2% | +4.2% | +4.2% | +4.4% | +4.4% | +4.4% | +4.4% | -61.7% | -60.3% | -57.4% | -73.0% | +5.6% | +3.6% | -6.7% |
Range$38.00M – $141.00M
CAGR-17.9%
Avg YoY Growth-15.7%
Median YoY Growth+4.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Stryker's medsurg and neurotechnology — d&a?
- Stryker (SYK) reported medsurg and neurotechnology — d&a of $56.00M in Q3 2025.
- How has Stryker's medsurg and neurotechnology — d&a changed year-over-year?
- Stryker's medsurg and neurotechnology — d&a decreased by 6.7% year-over-year, from $60.00M to $56.00M.
- What is the long-term trend for Stryker's medsurg and neurotechnology — d&a?
- Over 3 years (2021 to 2024), Stryker's medsurg and neurotechnology — d&a has grown at a -26.2% compound annual growth rate (CAGR), from $518.00M to $208.00M.
- What does medsurg and neurotechnology — d&a mean?
- The non-cash expense accounting for the aging of equipment and intangible assets in this segment.